ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Construction Money In Budget Earmarked For Frederick

February 9, 1990

Wyden Plans Bill To Induce Drug Firms to conduct Trials

October 29, 1993

Biggest NCI Budget Brings Large Headache: More Commitments, Rising Costs, Opportunities

December 8, 1989

Impetus to Proceed with a March Came From Talk Show

October 31, 1997

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

When Screening Mammography Meets Health Care Reform, Opinions Proliferate

February 4, 1994